Methods of evaluating patients using E-cadherin or vimentin

Patent metadata

Field	Value
Publication number	US-10101331-B2
Application number	US-201715444807-A
Country	US
Kind code	B2
Filing date	Feb 28, 2017
Priority date	Sep 17, 2012
Publication date	Oct 16, 2018
Grant date	Oct 16, 2018

Abstract

Methods and kits for the selection, evaluation, and/or treatment of a patient having cancer with an inhibitor of a glutamine-utilizing enzyme or a glutamine-depleting agent, by evaluating E-cadherin or vimentin expression are disclosed.

First claim

What is claimed:

1. A method of treating a patient having cancer, the method comprising:
acquiring an evaluation of or evaluating a patient sample, wherein the sample is evaluated for i) a level of E-cadherin expression or ii) a level of vimentin expression; and
if the level of E-cadherin expression is low, or the level of vimentin expression is high, as compared to a reference standard, then
administering to the patient in need thereof a therapeutically effective amount of an inhibitor of a glutamine-utilizing enzyme or a glutamine-depleting agent.

2. The method of claim 1 , wherein the level of E-cadherin expression is evaluated by the level of E-cadherin protein expression.

3. The method of claim 1 , wherein the level of vimentin expression is evaluated by the level of vimentin protein expression.

4. The method of claim 1 , wherein the patient is administered a therapeutically effective amount of an inhibitor of a glutamine-utilizing enzyme.

5. The method of claim 4 , wherein the inhibitor of a glutamine-utilizing enzyme inhibits a glutaminase.

6. The method of claim 5 , wherein the inhibitor is bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES).

7. The method of claim 1 , wherein the patient is administered a therapeutically effective amount of a glutamine depleting agent.

8. The method of claim 1 , wherein the cancer is lung cancer.

9. The method of claim 8 , wherein the lung cancer is non-small cell lung cancer.

10. A method of evaluating a patient having cancer for treatment with an inhibitor of glutamine-utilizing enzyme or a glutamine-depleting agent, the method comprising:
evaluating a patient sample, wherein the sample is evaluated for i) a level of E-cadherin expression or ii) a level of vimentin expression; and
if the level of E-cadherin expression is low, or the level of vimentin expression is high, as compared to a reference standard, then
determining to treat the patient with the inhibitor of glutamine-utilizing enzyme or the glutamine-depleting agent.

11. The method of claim 10 , wherein the sample is evaluated for i) a level of E-cadherin expression and ii) a level of vimentin expression.

12. The method of claim 10 , wherein the sample is evaluated for low or decreased pyruvate carboxylase expression compared to a reference standard.

13. The method of claim 10 , wherein the level of E-cadherin expression is evaluated by the level of E-cadherin protein expression.

14. The method of claim 10 , wherein the level of vimentin expression is evaluated by the level of vimentin protein expression.

15. The method of claim 10 , wherein the patient is evaluated for treatment with an inhibitor of a glutamine-utilizing enzyme.

16. The method of claim 15 , wherein the inhibitor of a glutamine-utilizing enzyme inhibits a glutaminase.

17. The method of claim 16 , wherein the inhibitor is bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES).

18. The method of claim 10 , wherein the patient is evaluated for treatment with a glutamine depleting agent.

19. The method of claim 10 , wherein the cancer is lung cancer.

20. The method of claim 19 , wherein the lung cancer is non-small cell lung cancer.

Assignees

• Agios Pharmaceuticals Inc
• Agios Pharmaceuticals Inc

Inventors

• Hurov Jonathan
• Choe Sung Eun
• Ulanet Danielle

Classifications

• G01N33/57557

  of other specific parts of the body, e.g. brain · CPC title

• G01N33/5752 Primary

  of the lungs · CPC title

• C12Y305/01001

  Asparaginase (3.5.1.1) · CPC title

• C12Q2600/106

  Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism · CPC title

• A61K31/433

  Thidiazoles · CPC title